BioCentury | Jul 31, 2020
Distillery Therapeutics

MAO-B, GABRA5 identified as astrocyte targets in subcortical stroke

DISEASE CATEGORY: Neurology INDICATION: Stroke Inhibiting MAO-B or GABRA5 could treat subcortical stroke by restoring regional glucose metabolism and alleviating diaschisis, neurological dormancy at sites distant from a focal brain injury. In a rat model...
BioCentury | Jul 31, 2020
Deals

Sangamo’s latest deal brings in Novartis, includes autism

In its second neurology-focused deal of the year, and sixth with a large biopharma, Sangamo has partnered with Novartis to turn its zinc finger gene modulation technology toward neurodevelopmental disorders, such as autism and intellectual...
BioCentury | Jul 29, 2020
Distillery Therapeutics

Inhibiting proteolytic activation of the receptor PAR2 for eosinophilic esophagitis

DISEASE CATEGORY: Inflammation INDICATION: Eosinophilic esophagitis Inhibiting the extracellular serine protease KLK5 or its substrate PAR2 could treat eosinophilic esophagitis, a food antigen-driven inflammatory disease. Single-cell sequencing revealed aberrant KLK5 expression in multiple cell populations...
BioCentury | Jul 22, 2020
Finance

Shonan iPark venture consortium seeks to boost bets on Japanese biotechs

A consortium established by Japanese life sciences accelerator Shonan iPark aims to grow the funding base for local biotechs by bolstering connections between investors. The Japan VC Consortium, launched Tuesday, will promote collaboration between Japanese...
BioCentury | Jul 9, 2020
Management Tracks

Goeltz to join Arcus as CFO following Gilead deal; plus changes at Corbus, MyoKardia, Humanigen, Aimmune, Avrobio, Syndax and more

Arcus Biosciences Inc. (NYSE:RCUS), named Bob Goeltz as CFO, effective August 1. Goeltz, who was SVP and CFO of Unity Biotechnology Inc. (NASDAQ:UBX), succeeds CFO and COO Rekha Hemrajani. In May, Gilead Sciences Inc. (NASDAQ:GILD)...
BioCentury | Jul 8, 2020
Finance

VelosBio jumps on megaround bandwagon with $137M series B

With its $137 million series B round Wednesday, VelosBio became the 50th biotech this year to raise a venture round topping the $100 million mark (see "Venture Megarounds Tracking to New Record” ). It is...
BioCentury | Jul 1, 2020
Emerging Company Profile

With potential for re-dosing, Carmine’s gene therapy tech attracts Takeda as partner

Carmine is developing red blood cell-based vesicles to deliver gene therapies, offering immunogenicity and manufacturing advantages over viral vector systems. The platform, which offers the potential for re-dosable gene therapies, led Takeda to become Carmine’s...
BioCentury | Jun 30, 2020
Product Development

Second death in Audentes gene therapy trial may highlight need for more careful dosing

The report of a second patient death in a trial of an AAV8-based gene therapy from Audentes and Astellas renewed decades-old concerns over the modality’s safety, but the adverse events may reflect a need for...
BioCentury | Jun 26, 2020
Finance

June 25 Quick Takes: Chi-Med rakes in $100M; plus bank rules rolled back, newco DeCART has June ties and more

Chi-Med raises $100M private placement  Hutchison China MediTech Ltd. (NASDAQ:HCM; LSE:HCM) raised $100 million Thursday in a private placement to General Atlantic through the sale of 4 million ADSs at $25. The price matches its...
BioCentury | Jun 26, 2020
Deals

Sosei Heptares gains new GPCR discovery partner in AbbVie

Sosei Heptares’ GPCR-targeting platform is continuing to draw attention from pharma with a deal with AbbVie that follows 2019 discovery collaborations with Genentech and Takeda. The Sosei Group Corp. (Tokyo:4565) unit will use its StaR...
Items per page:
1 - 10 of 3747
BioCentury | Jul 31, 2020
Distillery Therapeutics

MAO-B, GABRA5 identified as astrocyte targets in subcortical stroke

DISEASE CATEGORY: Neurology INDICATION: Stroke Inhibiting MAO-B or GABRA5 could treat subcortical stroke by restoring regional glucose metabolism and alleviating diaschisis, neurological dormancy at sites distant from a focal brain injury. In a rat model...
BioCentury | Jul 31, 2020
Deals

Sangamo’s latest deal brings in Novartis, includes autism

In its second neurology-focused deal of the year, and sixth with a large biopharma, Sangamo has partnered with Novartis to turn its zinc finger gene modulation technology toward neurodevelopmental disorders, such as autism and intellectual...
BioCentury | Jul 29, 2020
Distillery Therapeutics

Inhibiting proteolytic activation of the receptor PAR2 for eosinophilic esophagitis

DISEASE CATEGORY: Inflammation INDICATION: Eosinophilic esophagitis Inhibiting the extracellular serine protease KLK5 or its substrate PAR2 could treat eosinophilic esophagitis, a food antigen-driven inflammatory disease. Single-cell sequencing revealed aberrant KLK5 expression in multiple cell populations...
BioCentury | Jul 22, 2020
Finance

Shonan iPark venture consortium seeks to boost bets on Japanese biotechs

A consortium established by Japanese life sciences accelerator Shonan iPark aims to grow the funding base for local biotechs by bolstering connections between investors. The Japan VC Consortium, launched Tuesday, will promote collaboration between Japanese...
BioCentury | Jul 9, 2020
Management Tracks

Goeltz to join Arcus as CFO following Gilead deal; plus changes at Corbus, MyoKardia, Humanigen, Aimmune, Avrobio, Syndax and more

Arcus Biosciences Inc. (NYSE:RCUS), named Bob Goeltz as CFO, effective August 1. Goeltz, who was SVP and CFO of Unity Biotechnology Inc. (NASDAQ:UBX), succeeds CFO and COO Rekha Hemrajani. In May, Gilead Sciences Inc. (NASDAQ:GILD)...
BioCentury | Jul 8, 2020
Finance

VelosBio jumps on megaround bandwagon with $137M series B

With its $137 million series B round Wednesday, VelosBio became the 50th biotech this year to raise a venture round topping the $100 million mark (see "Venture Megarounds Tracking to New Record” ). It is...
BioCentury | Jul 1, 2020
Emerging Company Profile

With potential for re-dosing, Carmine’s gene therapy tech attracts Takeda as partner

Carmine is developing red blood cell-based vesicles to deliver gene therapies, offering immunogenicity and manufacturing advantages over viral vector systems. The platform, which offers the potential for re-dosable gene therapies, led Takeda to become Carmine’s...
BioCentury | Jun 30, 2020
Product Development

Second death in Audentes gene therapy trial may highlight need for more careful dosing

The report of a second patient death in a trial of an AAV8-based gene therapy from Audentes and Astellas renewed decades-old concerns over the modality’s safety, but the adverse events may reflect a need for...
BioCentury | Jun 26, 2020
Finance

June 25 Quick Takes: Chi-Med rakes in $100M; plus bank rules rolled back, newco DeCART has June ties and more

Chi-Med raises $100M private placement  Hutchison China MediTech Ltd. (NASDAQ:HCM; LSE:HCM) raised $100 million Thursday in a private placement to General Atlantic through the sale of 4 million ADSs at $25. The price matches its...
BioCentury | Jun 26, 2020
Deals

Sosei Heptares gains new GPCR discovery partner in AbbVie

Sosei Heptares’ GPCR-targeting platform is continuing to draw attention from pharma with a deal with AbbVie that follows 2019 discovery collaborations with Genentech and Takeda. The Sosei Group Corp. (Tokyo:4565) unit will use its StaR...
Items per page:
1 - 10 of 3747